Freed AI vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco AI medical scribe delivering SOAP notes within 2 minutes of a visit; no EHR integration needed, making it immediately accessible to solo clinicians and small practices.
About
Freed AI is a San Francisco-based medical technology startup that provides clinicians with an AI-powered medical scribe accessible via mobile app that records patient visit audio, transcribes the conversation, and generates a complete SOAP note formatted for direct paste into any EHR. Freed differentiates from other ambient scribing tools through its simplicity and accessibility — clinicians start and stop recordings with a tap, and notes are delivered within 2 minutes without requiring EHR integrations or complex IT deployment. The product's one-tap workflow and near-immediate turnaround make it accessible to solo practitioners and small clinics that need ambient scribing without enterprise procurement processes. Freed's AI is designed to capture not just what was said but what was clinically significant, filtering conversation content to produce concise, structured notes rather than verbose transcriptions. The company has grown rapidly through physician word-of-mouth and healthcare professional communities, with thousands of clinicians using the product. Founded in 2022, Freed has gained traction as a lightweight, affordable alternative to enterprise ambient scribing platforms.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.